L.KucheryanuV
A clean approach to stubborn adipose tissue
Our platform helps maximize your peptide investments
PMID 31076817
A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from the VENTURE trial published in Obesity
Check with your doctor immediately if any of the following side effects occur while taking tirzepatide: More common side effects stomach pain Less common side effects difficulty in breathing or swallowing fast heartbeat gaseous stomach pain heartburn recurrent fever skin itching, rash, or redness stomach fullness swelling of the face, throat, or tongue vomiting yellow eyes or skin Incidence not known anxiety bloating blurred vision change in vision changes in behavior chest tightness chills cold sweats coma confusion constipation cool, pale skin cough darkened urine depression dizziness fast heartbeat fever increased hunger indigestion large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs loss of appetite nausea nervousness nightmares pains in the stomach, side, or abdomen, possibly radiating to the back puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue seizures shakiness slurred speech thoughts of harming oneself unusual tiredness or weakness Other side effects of tirzepatide Some side effects of tirzepatide may occur that usually do not need medical attention
